A Radiotherapy Technique to Improve Dose Homogeneity Around Bone Prostheses by Williams, M. V. et al.
Sarcoma, March 2004, VOL. 8, NO. 1, 37–42
ORIGINAL ARTICLE
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Abstract
Purpose. Following limb conserving surgery for bone or soft tissue sarcoma, patients may require post-operative radiotherapy
to minimise the risk of local recurrence. In such circumstances the metal prosthesis reduces the dose in its shadow by
approximately 10% when using opposed fields. We describe a technique to boost the underdosed area to overcome this
problem.
Patients or subjects. Seven sequential patients presenting between 1995 and 2001 had their treatment individualised because
they had metal prosthesis in the treatment volume.
Methods. To improve the target dose homogeneity we used a custom-made keyhole cutout to boost the area in the shadow of
the prosthesis. The degree of attenuation caused by the metal prosthesis was estimated and a boost dose calculated. Exit
thermoluminescent dosimetry (TLD) was used to confirm the estimates made.
Results and discussion. Variation between patients was seen, demonstrating the need for exit TLD to individualise the
treatment plan. The use of a boost field provides a method to overcome under-dosage in the shadow of a metal prosthesis. It
improves dose homogeneity throughout the target volume and ensures adequate dose intensity around the prosthesis, the site
most at risk of local recurrence.
Introduction
Limb conserving surgery for primary bone tumours
is now a well-established practice and provides the
best available functional outcome.2,3,14,15 The
patients require removal of the affected bone, with
prosthetic replacement. Those at risk of local
recurrence can be identified by a low tumour
necrosis rate in the pathological specimen after
primary chemotherapy14 and close surgical excision
margins13 and pathological fracture.1 In this setting,
further local treatment with radiotherapy is often
recommended. Very rarely, soft tissue sarcomas can
involve the femur, requiring excision and prosthetic
replacement of the bone. This clinical scenario
typically also requires radiotherapy.
The principal component of prosthetic bone
replacements is titanium, which has an atomic
number (Z¼ 22) close to that of calcium (Z¼ 20),
but a higher electron density. Its electron density
relative to water is approximately 4, much greater
than that of bone (typically 1.1–1.3). This adversely
affects the depth–dose relationship in the tissues in
its ‘shadow’. Using conventional opposed fields to
irradiate a limb there is an under-dose of approxi-
mately 10% in this region due to attenuation.6 Metal
hip prostheses are encountered regularly in radio-
therapy planning; often avoidance is the preferred
course of action, though sometimes the presence
of the prosthesis is ignored where its impact on
treatment is minimal. The reason for avoiding metal
prostheses is 2-fold: firstly, it is usually impossible to
determine exactly the elemental composition of the
prosthesis, and, secondly, the majority of computer
planning system algorithms cannot fully predict
absorbed dose where metal is in the radiation
field. In the treatment of osteosarcoma where
resection is followed by insertion of a replacement,
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metal prosthesis bone, beams are arranged deliber-
ately to treat the area around the prosthesis:
avoidance is not an option.
We have developed a technique to overcome the
problem of attenuation using a simple low melting
point alloy (LMPA) cutout to compliment the
prosthesis. A one-dimensional effective depth inho-
mogeneity calculation algorithm is used to estimate
the dose reduction in the shadow of the prosthesis,
which is then boosted with small fields shaped with
individualised LMPA blocks. The technique descri-
bed here has been used to improve dose homo-
geneity in a series of seven patients treated since
1994, all those who have required radiotherapy for
sarcoma including a bone prosthesis.
Dosimetric studies on a phantom incorporating a
prosthesis carried out in-house demonstrate that
simple one-dimensional planning algorithms can
reasonably predict the effect of a prosthesis, provided
a value for the electron density is known.
Method and materials
To use our technique, the planning target volume
(PTV) and shielding blocks were drawn onto
anterior and posterior localisation films and a
representative set of patient outlines was taken to
cover the longitudinal extent of the PTV. A cross-
sectional impression of the prosthesis was transferred
from film to outline. All contours were digitised into
the planning system (TPS). In the absence of
additional information, it was assumed that the
prosthesis was titanium throughout, with a nominal
electron density of 3.75 relative to water, derived
from the CRC (Chemical Rubber Company) hand-
book.18 In reality, prostheses are constructed from
alloys and, more significantly, different parts of the
prosthesis are made from different alloys.
Anterior and posterior fields were applied and,
using the degree of attenuation predicted by the
treatment planning system (TPS), the isodose dis-
tribution was optimised by altering beam weightings
and normalisation point position (Fig. 1). Two
opposing customised fields shaped using LMPA to
match the prosthesis were applied to compensate for
the dose ‘shadow’ behind the prosthesis with a
weighting of approximately 10%: this improved the
dose distribution (Fig. 2). In addition, simple
compensation was added if required to account for
the longitudinal change in patient contour. An
estimate of the corrections required was calculated
using the Addenbrooke’s radiotherapy treatment
planning system (ARPS), using the one-dimensional
effective depth inhomogeneity algorithm, rather
than the modified Batho algorithm normally used
for 6-MV calculations. Where possible, a narrow
corridor of normal tissue, typically only skin and
subcutaneous tissue, was left outside the edges of the
fields. Minimal extra planning time is needed
because of the simplicity of this technique.
The boost field shapes were digitised from
localisation films (Fig. 3) and cut-out blocks were
constructed from high-density LMPA. Positioning
accuracy was checked at verification and subsequent
portal images were acquired on treatment days. Set-
up accuracy can be improved with electronic portal
imaging, which allows positional adjustments to be
made on-line (Fig. 4), and this has now been
incorporated into our routine protocol. An accuracy
of approximately 1mm can be achieved with this
technique. The time to set up and deliver this
treatment is approximately the same as a four-field
isocentric conformal plan using LMPA customised
shielding blocks, and with an immobilisation device.
The differential dose volume histogram (DVH)
(Fig. 5) demonstrates the improvement in dose
Fig. 1. Central axis dose distribution; parallel opposed fields;
prosthesis electron density 3.75. A large proportion of the PTV
receives 110%.
Fig. 2. Plan including opposing boost fields applied to improve
dose homogeneity.
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homogeneity achieved by compensating for the
attenuation by the prosthesis; the DVH approaches
a single peak and there is less spread in dose. This
DVH was derived from the central slice treatment
plan of a recent patient; a representative volume was
defined, avoiding the build-up region, for the
purposes of comparison.
To distinguish between the more common pros-
thesis compositions of titanium alloy and steel/
cobal chrome (electron density 7.0),9,10,12,18 and
to refine the boost field weighting, a second plan was
produced to compare with in vivo thermolumi-
nescent (TLD) exit dosimetry. This provides an
independent means of determining whether the
degree of attenuation estimated using the TPS is
acceptable. To achieve this, all but one beam is
deleted and 1 cm of bolus added to cover the exit
contour. Dose points 1 cm apart underneath the
bolus are recorded at the central axis and off axis
where it is suspected that a change in prosthesis
composition might occur. This arrangement is used
on the first day of treatment and the measurements
obtained are used to validate or adjust the boost dose
contribution for the remaining fractions.
Results
To date seven patients have been treated using this
technique. Their details and the reasons for post-
operative radiotherapy are summarised in Table 1.
With a median follow-up of 4 years (16 months–
8 years) there has been one patient who has devel-
oped local recurrence, distal to the area irradiated,
necessitating limb amputation and one patient who
has died of metastatic disease with local control in
the limb. A further patient has developed in-field
recurrence and lung metastases; she remains well
Fig. 3. Boost field customised block template, designed to
match the prosthesis’ shape.
Fig. 4. Daily portal image of a lower femur prosthesis to enable
on-line positional adjustments. Darker areas indicate imperfect
matching of the prosthesis and cut-out. In this case position is
considered clinically satisfactory. The image also shows that the
prosthesis has different components.
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and disease-free 2 years after local excisions. The
other four remain disease-free. Normal tissue effects
have been modest.
Table 2 shows the monitor units required for the
boost field (as a percentage of monitor units for the
full fields) as calculated, and after correction for exit
TLD. Whilst in most cases the calculated boost did
not change significantly after TLD measurements, in
one case (patient 5) it confirmed that there was a part
of the prosthesis of considerably higher density
(identified from localisation radiographs), requiring
an extra boost. In patient 7, the overall density was
higher than usual, requiring a greater boost. The
fields in patient 3 were not parallel opposed, hence
the difference between the fields.
Discussion
Our technique uses customised prosthesis-shaped
fields to boost the area shadowed by the prosthesis,
and in vivo dosimetry to validate the attenuation
estimate derived from the computer treatment
planning system. The use of published electron
density and the effective depth inhomogeneity
correction algorithm is a good predictor of the
degree of attenuation caused by a titanium alloy
prosthesis; the accuracy of the estimate of electron
density is not crucial due to the low boost field
weightings involved. The dosimetric impact that loss
of electronic equilibrium has at the tissue–prosthesis
interface has also been investigated: our measure-
ments show that dose enhancement due to back-
scatter upstream from the entry interface is greater
than the dose reduction downstream from the exit
interface, and this effect has a range of approximately
5mm. Our findings are consistent with published
data.20 Tissue immediately adjacent to the prosthesis
therefore receives an increased dose, but the volume
irradiated is small and the maximum dose increase is
estimated to be only 18% of local dose. We consider
that this should be a beneficial effect, particularly
since under-dose adjacent to the prosthesis is
avoided, and the small volume receiving the higher
dose is in the region where remaining tumour cells
are most likely to be located.
Beyond the range of this interaction our technique
improves dose homogeneity and eliminates the
under-dose of 8–15% which would otherwise exist
(Table 2).
We believe that this technique addresses an
important issue, namely potential underdose in the
shadow of the prosthesis in patients at high risk of
local recurrence. In the seminal description of the
correlation between intrinsic in vitro cellular radio-
sensitivity and clinical tumour control, Deacon et al.5
assigned osteosarcoma cells to the most radioresis-
tant category. This finding is consistent with
clinical data from as far back as the original work
by Cade, in the pre-chemotherapy era.4 Some early
dose–response studies performed on patients being
treated with primary radiotherapy using the Cade
technique found tumour sterilisation with doses
of 70–90 Gy, but persistent tumour at doses less
than or equal to 50 Gy.4 Other clinical series from
the pre-chemotherapy era have demonstrated poor
local control with doses which would be considered
standard today. In one series of 29 patients, no
durable local control was achieved with doses in the
range 45–60 Gy.11 This suggests that osteosarcoma
is relatively resistant to radiation. In an interesting
analysis of dose–time dependence and response,
Gaitan-Yanguas8 described a range of doses from
20 Gy up to 100 Gy, and reported a dose response
with doses above 60–70 Gy achieving a high
probability of local control.
In the context of a multi-modality treatment
programme, radiotherapy appears to have value for
local control, and indeed survival, in standard
doses.13
Other reports with small numbers of patients also
suggest a role for radical radiotherapy as part of a
multi-modality treatment programme.16
There is also evidence that local recurrence is
associated with poorer survival from metastatic
disease.19 This is consistent with the notion of
seeding from the recurrence, for which there is
both laboratory12 and clinical evidence.7 This under-
lines the importance of maximising local control,
both for local function and survival endpoints. These
data suggest that for the high risk patients we have
treated that it is important to maintain radiation
dose intensity. Given the relatively radioresistant
nature of this disease, maintenance of dose in the
shadow of the prosthesis, a zone of high risk is likely
to be of clinical value.
Because of the low numbers of patients who
require post-operative radiotherapy in such circum-
stances, it will not be possible to evaluate the impact
of this modification to standard treatment on local
recurrence rate and overall survival. However, we
believe it to be a valuable technique which is simple
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Fig. 5. DVH demonstrates quality of dose homogeneity with
and without boost fields.
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Table 1. Clinical details of seven patients treated
Year Diagnosis Age (years) Site Pre-radiotherapy treatment Indications for radiotherapy Follow-up time Current status
1 1995 Recurrent Haemangio-
endothelioma
21 Right leg (distal femur/
upper tibia)
Local excision Recurrence after primary
excision
8 years In field local control.
Disease free after amputation
for progression distal to RT
field
2 1998 Osteosarcoma 15 Left proximal humerus Pre-operative chemotherapy,
excision, second-line
chemotherapy
Low tumour necrosis rate,
involved surgical resection
margin
5 years In field recurrence and lung
metastases resected at 3 years.
Currently well and disease
free
3 1999 Recurrent osteosarcoma 17 Right lower femur Wide local excision of
recurrence
Recurrence after primary
excision
4 years Recurrence free
4 1999 High grade Leiomyosarcoma 58 Right quadriceps/femur Pre-operative chemotherapy,
excision
Femur encircled by soft
tissue and removed at
surgery
4 years Recurrence free
5 2000 Osteosarcoma 18 Right lower femur Pre-operative chemotherapy,
excision, second line
chemotherapy
Low tumour necrosis rate,
close resection margins,
involvement of knee joint
space
2.5 years Recurrence free
6 2000 Osteosarcoma 21 Right humerus Pre-operative chemotherapy,
excision
Pathological fracture at
presentation
16 months No local recurrence. Died of
metastatic disease
7 2001 High grade sarcoma rising in
low grade osteosarcoma.
34 Right tibia Excision, post-operative
chemotherapy
Pathological fracture at
presentation, close surgical
excision margins
2 years Recurrence free
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to instigate and does not add to the toxicity of
treatment.
Further refinement of this technique may be
possible using multileaf-collimation instead of alloy
blocks, and intensity-modulated radiotherapy to
account for the different attenuation properties of
the prosthesis’ composite parts.
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Table 2. Comparison of calculated and measured percentage
dose reduction attributable to attenuation by the prosthesis
% required for
boost (calculated)
(after TLD
measurement)
1 12.4% Not done
2 10.1% 10.1%
3 field 1: 14.8%
field 2: 10.9%
14.1%
9.4%
4 9.7% 9.4%
5 8.0% part 8.0%
part 17.9%
6 7.0% 7.0%
7 9.8% 14.5%
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